• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169044 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  / d( L9 X6 l* Q* R

# V, D4 }, c+ [; C
9 x% L: x! z6 r# m1 P. BSub-category:+ k$ x' e: |3 A
Molecular Targets
- b, x; [: |% {1 O2 o1 N2 l# n4 z
) J, G! c. }4 a5 L
/ z' t& R* x  S' DCategory:
6 A" n9 T1 B( r+ y3 DTumor Biology # Y9 M: a/ r3 m+ I" [

0 T! M& i/ b: Q  `6 n% w3 A  f: z
Meeting:
  h! g8 t, ]4 {$ t% f* k0 L( j2011 ASCO Annual Meeting
4 g5 \2 `3 f2 E: h" Z  M' c' A: j# D3 o' D# U3 E! Z
$ ?5 g/ w+ i  l0 U! \4 y. C
Session Type and Session Title:- }) B. z+ h9 I" h  c& Z  ?
Poster Discussion Session, Tumor Biology
3 X4 D! C* D( W7 A# s
) W# r8 A7 v" \$ ]1 F
' I% |! F5 X+ JAbstract No:% U; F  `3 W" Y0 F. m
10517
4 a$ M! x* l* @; W
2 i. N3 r# Q( b. A0 z( l( S: z7 l" G2 r1 i# n  F( ]4 Q4 x; L" @
Citation:
0 K9 S+ Q" z0 ?% y3 gJ Clin Oncol 29: 2011 (suppl; abstr 10517) . T3 Q$ l. E! M& c" p- y* ]* _

+ F$ {8 z1 ?. M& P0 s3 l$ B/ w0 L. J+ j5 |0 c
Author(s):
# [; C, V$ [$ G1 g. rJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 0 H! i. j& t1 p9 j/ ~& z
% D$ L9 y- O& s: T" H# ~) B, {
. `. y& O! I. ?4 b" e1 q# I7 m2 Z

6 z0 Y9 m8 l5 D+ IAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
6 ?1 z% V& M; n* w  ]. `! b& i  b
$ m3 }( @% v3 j, |3 J8 q. R& O8 ~% jAbstract Disclosures
/ j3 Q4 ~. N% T0 z1 F0 M
. P3 o1 H9 S, G; H; Q) C' Z1 SAbstract:
& r, [! c' x6 C. S  @$ k- T2 _4 V% _+ g. ?1 L6 W3 a

/ d+ m# B0 U3 T% S+ _Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
& E( k( L) r& k4 o6 B; U! k
( V- v$ l. S0 Q; }  s' L " S9 {/ r  J7 L2 l! R
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
: [* w9 s  m& M7 l* {, F& h5 W没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
0 u7 o) {) n; a+ R) i
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 * ^$ ^. H+ B! d; F0 X
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。* Y9 i4 l! I0 _, j% l! x
ALK一个指标医院要900多 ...

- V: ^; v& p9 ]2 @4 D  c平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
6 L8 R, N& e0 f6 Y" v/ Z$ F* o( R+ T% c, B# `
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表